Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
Frequently Asked Questions / Types of Cancer / Prostate Cancer / Prostate Cancer
Li Liu, MD
Last Modified: November 1, 2001
Dear OncoLink "Ask the Experts,"
Although there are comments and cases concerning younger (under 60) prostate cancer patients, there needs to be greater focus on these patients. As you well know, with PSA and free PSA tests, more and more younger patients are being diagnosed. The decisions that a younger man must face are a shift from those of the older, more traditional prostate cancer patient. While I appreciate that cancer studies are being done concerning this age group, there is really very little help specific to these patients.
Do you have any comments?
S.O.
Li Liu, MD, OncoLink Editorial Assistant, responds:
Dear S.O.:
Thank you for your interest and question.
Prostate cancer is a relatively rare disease in the younger population. From birth to age 39 years the chances of men developing invasive prostate cancer are 1 in 10,000; from 40 to 59 years, 1 in 103; and from 60 to 79 years, 1 in 8 (Scardino PT, et al. Human Pathology, 1992; 23:211). Only a few studies have addressed the specific issues of young patients with prostate cancer.
Patients younger than 65 appear to have similar outcomes after radiation therapy as older patients. A report (Freedman GM, et al. International Journal of Radiation Oncology, Biology, Physics, 1996; 35:243) demonstrated that the biological disease-free survival (survival with no elevation of PSA) of patients less than 65 was not significantly different than that of patients 65 and older treated with external beam irradiation. The results are similar to those of surgical series. A small series from the University of Mississippi Medical Center (Routh A, et al. Journal of the Mississippi State Medical Association, 1997; 38:1) reported that survival appeared to be slightly better in younger age groups when patients of all stages are pooled together. However, the number was too small to make any significant conclusions.
A younger patient whose tumor is encapsulated and thus elects surgery may find comfort in knowing the prostate is removed. From a statistics stand point, in order to identify the small difference between age groups, if there is any, a large-scale study is required. However, technically this can be difficult since the prevalence of prostate cancer in the younger population is so low. To my knowledge, there is no ongoing randomized cancer study addressing the issue of age difference.
As an oncologist, Dr. Giantonio provides care for many patients at the end of life, which he describes as a privilege and rewarding. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

